CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:
NDA 19-766/S043

Trade Name: Zocor Tablets

Generic Name: simvastatin

Sponsor: Merck & Company, Inc.

Approval Date: April 14, 2000
## Reviews / Information Included in this NDA Review.

<table>
<thead>
<tr>
<th>Review Type</th>
<th>Included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approval Letter</td>
<td>X</td>
</tr>
<tr>
<td>Approvable Letter</td>
<td></td>
</tr>
<tr>
<td>Labeling</td>
<td></td>
</tr>
<tr>
<td>Medical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Chemistry Review(s)</td>
<td></td>
</tr>
<tr>
<td>Pharmacology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Statistical Review(s)</td>
<td></td>
</tr>
<tr>
<td>Microbiology Review(s)</td>
<td></td>
</tr>
<tr>
<td>Clinical Pharmacology/ Biopharmaceutics Review(s)</td>
<td></td>
</tr>
<tr>
<td>Administrative/Correspondence Document(s)</td>
<td>X</td>
</tr>
</tbody>
</table>
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-766/S043

APPROVAL LETTER
NDA 19-766/S-043

Merck & Co., Inc.
Attention: Michael Elia, M.D.
Director, Regulatory Affairs
Sumneytown Pike, P.O. Box 4
BLA-20
West Point, PA 19486

Dear Dr. Elia:

Please refer to your supplemental new drug application dated November 16, 1999, received November 17, 1999, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zocor (simvastatin) Tablets.

This “Changes Being Effected” supplemental new drug application provides for correcting the inconsistency noted between the NDA and the Caguas, Puerto Rico lubrication parameters for 5 mg tablets.

We have completed the review of this supplemental application and it is approved.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Margaret Simoneau, R.Ph., Regulatory Management Officer, at (301) 827-6418.

Sincerely,

Stephen K. Moore 3/1/00
Stephen K. Moore, Ph.D.
Chemistry Team Leader I for Division of Metabolic and Endocrine Drug Products, (HFD-510) DNDC II, Office of New Drug Chemistry Center for Drug Evaluation and Research
CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
NDA 19-766/S043

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
November 16, 1999

Solomon Sobel, M.D., Director  
Division of Metabolism and Endocrine Drug Products  
HFD-510, Room 14B-04  
Office of Drug Evaluation II (CDER)  
5600 Fishers Lane  
Food and Drug Administration  
Rockville, MD 20857

Dear Dr. Sobel:

NDA 19-766: Tablets ZOCOR™ (Simvastatin)  
SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED (CBE)  
Chemistry Section: Tablets ZOCOR™, 5 mg

Pursuant to Section 505(b) of the Food, Drug and Cosmetic Act and in accordance with 21 CFR 314.70(c), Merck Research Laboratories (MRL), a division of Merck & Co., Inc., submits a supplement to NDA 19-766.

As indicated on the attached Form FDA 356h, this supplemental application provides for changes in the Chemistry section of the approved New Drug Application (NDA) for Tablets ZOCOR™ (simvastatin).

In 1996, Tablets ZOCOR® 5 mg was initiated and validated utilizing the modified lubrication parameters provided in the attached supplement at the Merck Manufacturing Division (MMD) facility located in Caguas, Puerto Rico. The validated manufacturing process of the Wilson, North Carolina facility utilizes the NDA filed lubrication parameters. During the validation in 1996, Caguas and Wilson validation data were reviewed and found to be acceptable. During the recent annual review of the NDA, it was determined that this site dichotomy was not reflected in the filed manufacturing process description. Therefore, with this letter, MRL is providing a CBE supplement to NDA 19-766 correcting the inconsistency noted between the NDA filed with the Agency and the Caguas manufacturing lubrication parameters.

Attachment 1 contains the following CMC information:

- An Updated Tablets ZOCOR® 5 mg Manufacturing Process Description.
- Multi-point dissolution profiles for Tablets ZOCOR® 5 mg film-coated at the Caguas and Wilson facilities.
- Batch analysis of representative batches of film-coated tablets at Caguas and Wilson.
- Stability data for one lot of Tablets ZOCOR® 5 mg film-coated at the Caguas facility (Long-term stability data will be provided in subsequent Annual Reports).
Attachment 2 contains Merck’s request for a categorical exclusion from the requirements to prepare an Environmental Assessment under 21 CFR 25.31(a).

Unless otherwise notified, Merck & Co. would like to continue distribution of Tablets ZOCOR® 5 mg manufactured at the Caguas facility on or about November 18, 1999.

In accordance with the Food and Drug Administration Modernization and Accountability Act of 1997, as indicated on the attached Form 3397, no fee is required for this supplemental application.

Pursuant to 21 CFR 314.70(a), a complete field copy of this amendment to the above-referenced supplemental application has been submitted to the FDA Philadelphia District Office.

As required by Section 306(k)(1) of the Generic Drug Enforcement Act [21 U.S.C. 335a (k) (1)], we hereby certify that, in connection with this application, Merck & Co. Inc. did not and will not use in any capacity the services of any person debarred under subsections 306 (a) or (b) of the Act.

We consider the filing of this Supplemental New Drug to be a confidential matter, and request that the Food and Drug Administration not make its content, nor any future communications in regard to it, public without first obtaining the written permission of Merck & Co., Inc.

Questions concerning this information should be directed to Robert E. Silverman, MD, PhD (610-397-2944) or, in my absence, to Bonnie J. Goldmann, M.D. (610-397-2383).

Sincerely,

Robert E. Silverman, MD, PhD
Senior Director, Regulatory Affairs
DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

USER FEE COVER SHEET

See Instructions on Reverse Side Before Completing This Form

1. APPLICANT'S NAME AND ADDRESS
   Merck & Co., Inc.
   Summittown Pike, BLA-10
   P. O. Box 4
   West Point, PA 19486

2. TELEPHONE NUMBER (include Area Code)
   (610) 397-2383

3. PRODUCT NAME
   ZOCOR (Simvastatin)

4. DOES THIS APPLICATION REQUIRE CLINICAL DATA FOR APPROVAL?
   IF YOUR RESPONSE IS "NO" AND THIS IS FOR A SUPPLEMENT, STOP AND SIGN THIS FORM.
   IF RESPONSE IS "YES", CHECK THE APPROPRIATE RESPONSE BELOW
   - THE REQUIRED CLINICAL DATA ARE CONTAINED IN THE APPLICATION
   - THE REQUIRED CLINICAL DATA ARE SUBMITTED BY REFERENCE TO
     (APPLICATION NO. CONTAINING THE DATA).

5. USER FEE I.D. NUMBER
   NO19766

6. LICENSE NUMBER / NDA NUMBER

7. IS THIS APPLICATION COVERED BY ANY OF THE FOLLOWING USER FEE EXCLUSIONS? IF SO, CHECK THE APPLICABLE EXCLUSION.
   - A LARGE VOLUME PARENTERAL DRUG PRODUCT
     APPROVED UNDER SECTION 505 OF THE FEDERAL
     FOOD, DRUGS, AND COSMETIC ACT BEFORE 9/1/92
     (Self Explanatory)
   - A 505(b)(2) APPLICATION THAT DOES NOT REQUIRE A FEE
     (See Item 7, reverse side before checking box.)
   - THE APPLICATION QUALIFIES FOR THE ORPHAN
     EXCEPTION UNDER SECTION 735(a)(1)(F) OF THE FEDERAL
     DRUG, AND COSMETIC ACT
     (See Item 7, reverse side before checking box.)
   - THE APPLICATION IS A PEDIATRIC SUPPLEMENT THAT
     QUALIFIES FOR THE EXCEPTION UNDER SECTION 735(a)(1)(F) OF
     THE FEDERAL DRUG, AND COSMETIC ACT
     (See Item 7, reverse side before checking box.)
   - THE APPLICATION IS SUBMITTED BY A STATE OR FEDERAL
     GOVERNMENT ENTITY FOR A DRUG THAT IS NOT DISTRIBUTED
     COMMERCIALLY
     (Self Explanatory)

FOR BIOLOGICAL PRODUCTS ONLY
   - WHOLE BLOOD OR BLOOD COMPONENT FOR
     TRANSFUSION
   - A CRUDE ALLERGENIC EXTRACT PRODUCT
   - AN APPLICATION FOR A BIOLOGICAL PRODUCT
     FOR FURTHER MANUFACTURING USE ONLY
   - AN "IN VITRO" DIAGNOSTIC BIOLOGICAL PRODUCT
     LICENSED UNDER SECTION 351 OF THE PHS ACT
   - BOVINE BLOOD PRODUCT FOR TOPICAL
     APPLICATION LICENSED BEFORE 9/1/92

8. HAS A WAIVER OF AN APPLICATION FEE BEEN GRANTED FOR THIS APPLICATION?
   - YES    - NO
   (See reverse side if answered YES)

A completed form must be signed and accompany each new drug or biologic product application and each
supplement. If payment is sent by U.S. mail or courier, please include a copy of this completed form with paym.

Public reporting burden for this collection of information is estimated to average 30 minutes per response, including the time for re
structions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of infor
Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to

DHHS, Reports Clearance Officer
Paperwork Reduction Project (0910-0297)
Hubert H. Humphrey Building, Room 531-H
200 Independence Avenue, S.W.
Washington, DC 20201

An agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it
displays a currently valid OMB control number.

Please DO NOT RETURN this form to this address.

SIGNATURE OF AUTHORIZED COMPANY REPRESENTATIVE
Bonnie J. Goldmann, M.D.
Vice President, Domestic Liaison
Regulatory Affairs

DATE
November 12, 2001

FORM FDA 3397 (5/96)